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Malignancies of the urinary tract and their relation to
analgesic abuse
ULLA BENGTSSON, SONNY JOHANSSON and LENNART ANGERVALL
Departments of Nephrology and Pathology, Sahigren's Hospital, University of Gäteborg, Sweden
The first observations of a relationship between
analgesic abuse and urothelial renal pelvic tumors
came from Sweden. In 1965, Hultengren, Lagergren,
and Ljungqvist [1] described the epithelial renal pel-
vic tumors in six patients who had renal papillary
necrosis. Five of these patients were known to abuse
phenacetin-containing drugs. In 1968, Bengtsson et
al [2] reported on the development of such tumors in
nine out of 104 patients with previously known
nephropathy associated with analgesic abuse. Two
other patients in this series developed uroepithelial
bladder tumors. The average follow-up period was
five years. All of the patients had taken compounds
containing phenacetin, phenazone, and caffeine. A
consumption of one gram of phenacetin daily for at
least one year was classified as abuse. Even patients
with a smaller daily intake often reached a total
consumption of several kilograms and were therefore
included in the group of abusers. This study from the
Medical Department I, Sahigren's Hospital, Göte-
borg, prompted us to perform further studies of all
patients with epithelial renal pelvic tumors admitted
to the cooperating Surgical Department I during the
years 1960 to 1967. Fourteen of the 29 patients
reviewed had been abusers of phenacetin-containing
drugs. The mean age of the patients in this group was
lower, and females were in majority, while in the
nonabusers (15 patients) elderly men with prostatic
hyperplasia predominated.
Our further studies on the relationship of renal
pelvic tumors to analgesic abuse were then focused
to Huskvarna-Jonkoping, a district with a known
high consumption of phenacetin-containing drugs
[311. The high incidence of analgesic nephropathy in
this district had earlier been reported by Nordenfelt
and Ringertz [4] and Grimlund [5]. In the county
hospital, 15 cases of urothelial tumors of the renal
pelvis had been diagnosed between 1960 and 1968
[3]. Ten, possibly 12, of the patients had been
abusers of a phenacetin-containing powder.
In the 1970's, there have been several reports on
cases of epithelial tumor of the renal pelvis or the
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bladder in abusers of phenacetin-containing drugs
from other parts of the world, although the number
of patients in these reports usually has been small [6—
18]. The experience of a total of 62 patients from
Sweden with abuse of phenacetin-containing drugs
and urothelial tumors of the renal pelvis was report-
ed by Johansson et al in 1974 [191. In a later publica-
tion, the prognosis in patients with renal pelvic
tumors was studied with respect to the influence of
different clinical and morphologic variables [201.
Epidemiology
The total incidence of epithelial tumors of the renal
pelvis in Sweden is low. During the early 1960's, the
average yearly incidence was one case per 183,000
inhabitants, and during the later 1960's it was one
case per 156,000, according to the Swedish Cancer
Registry [21]. This disease has usually been
described as a predominantly male disease, with a
ratio of four men to one woman [221. In Sweden, this
sex ratio was 2:1 in 1958. The sex ratio, however, has
been reversed in the reports on renal pelvic tumors in
analgesic abusers. In the study by Hultengren et al
[1], all six patients were females, and in our first
study [2] the sex ratio was 1:2.5. This fits with the
epidemiology of analgesic abuse, since women have
more frequently been addicted to phenacetin-con-
taming drugs than men [23—25]. The only exception
from this pattern is the findings among the workers at
the Huskvarna factory. A traditionally heavy abuse
of phenacetin-containing drugs predominantly in
males had prevailed there since the Spanish influenza
pandemic in 1918—19 19. This was reflected in a high-
er death rate due to uremia in males, than in fe-
males [4, 5]. In the investigation by Angervall et al,
it turned out that 10 out of 15 patients with renal
pelvic tumors in the nearby county hospital had
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come from Huskvarna [31. Later on, 1973, Zetter-
lund [261 reported on an additional number of 14
cases of renal pelvic tumors in phenacetin abusers
from this district. The Huskvarna factory has 1,800
workers, the town of Huskvarna has 13,000 inhabi-
tants, and the county has 100,000 inhabitants. The
Swedish Cancer Registry has disclosed no accumula-
tion of renal pelvic carcinoma in other places with
factories manufacturing similar products as in Husk-
varna. The total consumption of phenacetin-contain-
ing drugs had been recorded to be ten times higher in
Huskvarna than in other comparable towns [51. In
GOteborg, the city with the largest number of report-
ed cases of renal pelvic tumors in analgesic abusers,
there were few factory workers. Instead, housewives
were in majority. Thus, there are no data speaking in
favor of an environmental or occupational factor.
Clinical history and clinical findings
In the Swedish series, the great majority of
patients had taken compounds containing 0.5 g of
phenacetin, 0.5 g of phenazone (antipyrine), and 0.1
g of caffeine. The other patients had used similar
compounds, only the dose relations of phenacetin,
phenazone, and caffeine varied somewhat. A few
patients had for shorter periods of time also used
compounds of phenacetin and salicylates. In 38
patients of the Göteborg study [191, fairly detailed
data of the abuse were available, and these data are
given in Table 1. For the remaining patients it could
only be stated that there had been a heavy abuse of
the aforementioned drugs over several years. The
manifest development of the tumor often came after
cessation of the drug abuse.
Hematuria was the major symptom leading to the
diagnosis of the renal pelvic tumor in the analgesic
abusers. Gross hematuria, often combined with renal
colic, was found in 75% of the patients. Microscopic
hematuria was found in 14% of the patients. Retro-
spectively, it could be noted that gross hematuria
had often been heralded by microscopic hematuria
for several months. Five to 17 yr eariier, one-fourth
of the patients had had episodes of hematuria and/or
acute attacks of pyelonephritis, probably due to tem-
porary obstruction of the urinary tract by seques-
Table 1. Consumption of phenaeetin in 38 patients with
uroepithelial tumors of the renal pelvi?
Consumption
kg
Exposure
time
yr
Induction
time
yr
Mean 9.1 17 22
Range 1.5—27 4—30 9—42
a Reprinted with permission from Cancer [191
tered renal papilae. Because of the history of pre-
vious nephropathy, gross hematuria did not always
alarm the patients, and thus the diagnosis of the
tumor was sometimes delayed until the next routine
control. Nearly all the patients had impaired renal
function, with a serum creatinine of 1.3 mg/l00 ml or
higher. Arterial hypertension was present in more
than half of the patients. A history of urinary tract
infection was recorded in 64% of the patients.
Patients with analgesic nephropathy should be fol-
lowed closely, and even the finding of discrete micro-
scopic hematuria should prompt reinvestigation of
urine cytology, urography, and when necessary,
retrograde pyelography [27]. The diagnostic ac-
curacy of urine cytology is high except in patients with
total obstruction of the urinary tract or low grade
tumors [28].
Pathologic findings
The renal pelvic tumors in phenacetin abusers
have been urothelial with varying degree of differen-
tiation, the majority of them wholly or partly papil-
lary. In occasional cases, areas of squamous cell
differentiation have been observed. There has been
no case of pure squamous cell carcinoma in the
Swedish series, but a few such tumors were reported
in a Swiss series [16]. One investigator has even
discussed a relationship between phenacetin abuse
and renal cell carcinoma [18]. Some five percent of
the patients have had simultaneous bilateral pelvic
tumors. Most of the papillary tumors have been
smaller than 3.5 cm, and most of the solid tumors,
larger than 3.5 cm.
A significant, higher relative frequency of women
has been observed among patients with the larger
tumors. With increasing tumor size, a tendency to
lower differentiation of the tumor has been observed.
Infiltration has been noted, particularly among the
high grade tumors [19]. In some instances, the
tumors have been localized wholly or partly to the
renal papilla, but in most cases the tumors were
localized to the calyces or pelvic ampulla [2] (Fig. I).
Thirty-five percent of the patients have had an
earlier, simultaneous or later development of urothe-
hal tumor in the ipsilateral or contralateral ureter and
pelvis or in the urinary bladder. Bladder tumors were
found in about 13%. In most cases, the multiple
tumors have been of the same histologic grade as the
primary renal pelvic tumor. Distant metastases were
found in 43% of the cases at autopsy, lungs, liver,
and bone system being the predominant sites [19].
Papillary necrosis has been a prominent feature in
the published series of renal pelvic tumors in analge-
sic abusers. No less than 57 of the 62 patients in the
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Fig. 1. A urothelial pelvic tumor infiltrating a necrotic papillae. (Reprinted with permission from Cancer [19].)
Swedish series had papillary necrosis, including pap-
illary necrosis with calcification (Fig. 1), and in three
instances bone formation [19]. The papillary necro-
sis was usually bilateral. In this series, there were
three patients with a heavy abuse history, tumors of
the renal pelvis without signs of nephropathy and
papillary necrosis clinically, roentgenologically, and
histologically, indicating that a preexisting nephropa-
thy is not a sine qua non for the development of renal
pelvic tumors in abusers of phenacetin-containing
drugs.
Prognosis
In our first study [2], we found that the tumor
differentiation tended to be lower in patients with
analgesic abuse than in nonabusers. Furthermore,
the death rate within two years was twice as high in
the abusers, despite the fact that the mean age was 11
yr lower among them than among the nonabusers (56
and 67 yr, respectively). In a later prognostic study
of a Swedish national series of renal pelvic tumors
[20], the five-year survival rate in patients operated
upon was 33% among females and 50% among
males. Out of 94 patients with epithelial tumors, 25
patients had a verified or probable abuse of phenace-
tin-containing drugs, and out of them only six (24%)
survived five years. The five-year survival was 6/15
(40%) among those who could be submitted to cura-
tive operative procedures. These data indicate a
poorer prognosis in patients with analgesic abuse,
and the relatively high frequency of females in this
group may explain the sex difference in five-year
survival in the total series. The main predictor of
the prognosis was the extent of the invasive growth
of the tumor. Tumor grade and tumor structure also
exhibited some influence on the prognosis. One
major factor contributing to the poorer prognosis of
renal pelvic carcinoma in analgesic abusers is the
coexisting chronic nephropathy in the great majority
of patients. With advanced renal impairment, opera-
tive removal of the tumor cannot be extensive
enough. Only resection of the kidney and/or the renal
pelvis can be performed, and in azotemic patients
only palliative operations or no operation at all can
be carried out.
The progress of analgesic nephropathy is usually
slow, providing the analgesic abuse has ceased and if
factors which might accelerate renal impairment,
such as hypertension and urinary tract infections, are
adequately treated. We have seen several patients
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with a glomerular filtration rate of 15 to 20 mllmin
and serum creatinine levels of 3 to 4 mg/100 ml who
have maintained an unchanged renal function after
10 to 15 yr. To avoid a progressive course into
uremia, it is therefore important that an operation
should not leave a patient with a renal function below
the aforementioned levels. Split function studies may
be necessary to determine the surgical approach:
nephrectomy or parenchyma-saving resection.
Carcinogenic factors
Occupational bladder cancer was first described
by Rehn, 1895, in dye factory workers [29]. Later,
experimental and epidemiologic investigations pro-
vided evidence for carcinogenicity of 1- and 2-
naphthylamine, 4-aminodiphenyl, and benzidine
[30—33]. These chemical products were removed
from the dye and rubber industry. Also chiornapha-
zinc, a drug used against hematologic malignancies,
and a derivative of 2-naphthylamine were shown to
induce epithelial bladder tumors [34, 35].
The etiology of renal pelvic tumors has not been
defined. A high incidence of renal pelvic carcinoma
has been reported in cases of interstitial nephritis in
the Balkan states [37, 38], but the etiology has not
yet been clarified. Renal pelvic tumors have been
reported in patients subjected to retrograde pyelog-
raphy with the radioactive substance thorotrast [36].
The induction time was 22.5 yr, which is almost
identical to the induction time for the tumors in the
analgesic abusers and close to the induction time for
occupational bladder tumors [31]. There is a further
similarity between the occupational bladder tumors
and renal pelvic tumors associated with analgesic
abuse: the induction time often exceeded the expo-
sure or consumption time by some years.
The incidence of bladder carcinoma is 15 times
higher than the incidence of renal pelvic carcinoma
according to the Swedish Cancer Registry [21].
Thus, there should be some local predisposing factor
to account for the localization of the tumor to the
renal pelvis. Inflammatory changes and papillary
necrosis are suggested to be such factors. These
factors per Se, however, seem not to cause tumor
development, since in a control series of 88 nonabu-
sers with chronic pyelonephritis in the Goteborg
study, no tumor developed during the same period of
follow-up [2]. In this connection, it is of interest that
two out of eight dye workers with renal pelvic
tumors 1139] had malformed kidneys [40, 411.
Carcinogenic aromatic amines and amides are acti-
vated by N-hydroxylation and subsequently by
esterification of the N-hydroxy group [42]. Phenace-
tin is an aromatic amide with N-hydroxylated metab-
olites [43, 44]. The major pathways in phenacetin
metabolism are shown in Figure 2. Peroral adminis-
tration of N-hydroxyphenacetin to rats induced a
high frequency of hepatomas [451. Nitrosation of
phenacetin has been demonstrated to yield a sub-
stance which induces tumors locally upon s.c.
administration [46]. Nery [44] found azoxy-4-
ethoxy-benzene, a condensation product of N-
hydroxy-phenacetin or N-hydroxy-4-phenetidine, in
the urine of rats fed with phenacetin. This indicates a
concentration of N-hydroxylated metabolites in the
kidney and a highly probable carcinogenic hazard.
Peroral administration of phenacetin to female Spra-
gue-Dawley rats for up to 110 weeks induced a high
incidence of urothelial, partly papillary, hyperplasia
of the renal papilla. The hyperplastic changes were in
most cases associated with vascular changes and/or
calcification (Fig. 3) [47, 48].
Phenazone and caffeine were common ingredients
of the analgesic compounds used by the patients in
the present study. The chemical structure of phena-
zone indicates no relation to known urinary tract
carcinogens, but the metabolism has been less close-
ly studied, and a carcinogenic effect of this agent
cannot be ruled out. Caffeine has been shown to be
mutagenic in lower organisms, for example, Droso-
phila and human dividing cells in vitro [491. An
association between coffee-drinking and bladder
cancer has been suggested [50], but its etiologic
importance seems doubtful. In Sweden, the con-
sumption of coffee per capita is among the highest in
the world, but the total incidence of urinary tract
carcinoma is lower than in most other western
countries.
Conclusions
Accumulating circumstantial evidence for a carci-
nogenic effect by phenacetin-containing drugs has
been presented. The present knowledge of the
metabolism of phenacetin and the chemical relation-
ship of some of these metabolites to known urinary
tract carcinogens gives support to the view that
phenacetin is a crucial factor in the development of
urothelial tumors in man. Further support is given by
rat experiments, in which a high frequency and a
high degree of papillary epithelial hyperplasia have
been induced after long-term phenacetin-feeding.
Further investigations, however, are needed to rule
out a carcinogenic effect by other components in the
analgesic compounds.
Summary
A relationship between analgesic abuse and urot-
helial renal pelvic tumors was first observed in 1965.
Since then more than 100 cases of such tumors have
been reported in abusers of phenacetin-containing
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Fig. 2. The major pathways in
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Fig. 3. Severe vascular changes of the vasa recta with thrombus formation and calcfIca-
tion in association with severe diffuse urothelial hyperplasia in a Sprague-Dawley rat fed
phenacetin for 110 weeks. Reprinted with permission from Acta Pathol Microbiol Scand [481.
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drugs; most of these cases have been from Sweden.
Many patients had a preexisting nephropathy with
renal papillary necrosis. The total consumption of
the drugs could be estimated to several kilograms,
and the average period of consumption was 17 yr in
the Goteborg study. The manifest development of
the tumor often came a few years after the cessation
of the drug abuse. The clinical picture and the patho-
logic findings are described and the five-year survival
rate is given. Multiple tumors in the urinary tract
were common. Carcinogenic factors are discussed.
Phenacetin is an aromatic amide with N-hydroxylat-
ed metabolites, closely related to known carcino-
genic amines like the naphthylamines which earlier
caused occupational bladder cancer. Furthermore,
the data on exposition (consumption) time and tumor
induction time were very similar in occupational
bladder cancer and in renal pelvic cancer related to
analgesic abuse. Animal experiments of long-term
phenacetin feeding have produced a high degree of
papillary epithelial hyperplasia. Further investiga-
tions are under way.
Reprint requests to Dr. U. Ben gtsson, Deportment of Nephrolo-
gy, University Hospital, Land, Sweden.
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